Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have been given an average rating of "Moderate Buy" by the nine ratings firms that are presently covering the company, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $56.57.

Several analysts recently commented on the stock. StockNews.com lowered shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Friday, February 14th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective for the company.

Insider Buying and Selling at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of Agios Pharmaceuticals stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now directly owns 149,220 shares in the company, valued at $3,864,798. The trade was a 4.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.93% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of AGIO. Summit Investment Advisors Inc. boosted its holdings in Agios Pharmaceuticals by 7.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Agios Pharmaceuticals by 4.4% during the 4th quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after acquiring an additional 582 shares in the last quarter. KBC Group NV increased its holdings in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock valued at $86,000 after acquiring an additional 611 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Agios Pharmaceuticals by 1.2% during the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after acquiring an additional 708 shares during the last quarter. Finally, Atria Investments Inc raised its stake in shares of Agios Pharmaceuticals by 6.9% in the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after acquiring an additional 737 shares in the last quarter.

Agios Pharmaceuticals Trading Up 1.9 %

NASDAQ:AGIO traded up $0.52 during midday trading on Tuesday, hitting $27.66. 590,693 shares of the stock were exchanged, compared to its average volume of 711,909. The company has a market capitalization of $1.58 billion, a price-to-earnings ratio of 2.44 and a beta of 0.83. Agios Pharmaceuticals has a one year low of $23.42 and a one year high of $62.58. The business has a 50-day moving average price of $30.77 and a two-hundred day moving average price of $38.68.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. Sell-side analysts forecast that Agios Pharmaceuticals will post -6.85 EPS for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.